Literature DB >> 29386392

Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.

Yulan Xiong1,2,3, Stewart Neifert4,2, Senthilkumar S Karuppagounder4,2,5, Qinfang Liu3, Jeannette N Stankowski4,2, Byoung Dae Lee4,2, Han Seok Ko4,2,5,6, Yunjong Lee4,2, Jonathan C Grima4,2,7, Xiaobo Mao4,2, Haisong Jiang4,2, Sung-Ung Kang4,2, Deborah A Swing8, Lorraine Iacovitti9,10, Lino Tessarollo8, Ted M Dawson1,2,5,6,7,11, Valina L Dawson1,2,5,6,7,12.   

Abstract

Mutations in LRRK2 are known to be the most common genetic cause of sporadic and familial Parkinson's disease (PD). Multiple lines of LRRK2 transgenic or knockin mice have been developed, yet none exhibit substantial dopamine (DA)-neuron degeneration. Here we develop human tyrosine hydroxylase (TH) promoter-controlled tetracycline-sensitive LRRK2 G2019S (GS) and LRRK2 G2019S kinase-dead (GS/DA) transgenic mice and show that LRRK2 GS expression leads to an age- and kinase-dependent cell-autonomous neurodegeneration of DA and norepinephrine (NE) neurons. Accompanying the loss of DA neurons are DA-dependent behavioral deficits and α-synuclein pathology that are also LRRK2 GS kinase-dependent. Transmission EM reveals that that there is an LRRK2 GS kinase-dependent significant reduction in synaptic vesicle number and a greater abundance of clathrin-coated vesicles in DA neurons. These transgenic mice indicate that LRRK2-induced DA and NE neurodegeneration is kinase-dependent and can occur in a cell-autonomous manner. Moreover, these mice provide a substantial advance in animal model development for LRRK2-associated PD and an important platform to investigate molecular mechanisms for how DA neurons degenerate as a result of expression of mutant LRRK2.

Entities:  

Keywords:  LRRK2; Parkinson’s disease; neurodegeneration; α-synuclein

Mesh:

Substances:

Year:  2018        PMID: 29386392      PMCID: PMC5816154          DOI: 10.1073/pnas.1712648115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

2.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

3.  LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis.

Authors:  Samer Matta; Kristof Van Kolen; Raquel da Cunha; Geert van den Bogaart; Wim Mandemakers; Katarzyna Miskiewicz; Pieter-Jan De Bock; Vanessa A Morais; Sven Vilain; Dominik Haddad; Lore Delbroek; Jef Swerts; Lucía Chávez-Gutiérrez; Giovanni Esposito; Guy Daneels; Eric Karran; Matthew Holt; Kris Gevaert; Diederik W Moechars; Bart De Strooper; Patrik Verstreken
Journal:  Neuron       Date:  2012-09-20       Impact factor: 17.173

4.  LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.

Authors:  Amaia M Arranz; Lore Delbroek; Kristof Van Kolen; Marco R Guimarães; Wim Mandemakers; Guy Daneels; Samer Matta; Sara Calafate; Hamdy Shaban; Pieter Baatsen; Pieter-Jan De Bock; Kris Gevaert; Pieter Vanden Berghe; Patrik Verstreken; Bart De Strooper; Diederik Moechars
Journal:  J Cell Sci       Date:  2015-02-01       Impact factor: 5.285

5.  Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.

Authors:  Xianting Li; Jyoti C Patel; Jing Wang; Marat V Avshalumov; Charles Nicholson; Joseph D Buxbaum; Gregory A Elder; Margaret E Rice; Zhenyu Yue
Journal:  J Neurosci       Date:  2010-02-03       Impact factor: 6.167

6.  Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Authors:  Yanping Li; Wencheng Liu; Tinmarla F Oo; Lei Wang; Yi Tang; Vernice Jackson-Lewis; Chun Zhou; Kindiya Geghman; Mikhail Bogdanov; Serge Przedborski; M Flint Beal; Robert E Burke; Chenjian Li
Journal:  Nat Neurosci       Date:  2009-06-07       Impact factor: 24.884

7.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

8.  Regulation of LRRK2 expression points to a functional role in human monocyte maturation.

Authors:  Jonathan Thévenet; Rosanna Pescini Gobert; Robertus Hooft van Huijsduijnen; Christoph Wiessner; Yves Jean Sagot
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

9.  No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.

Authors:  Marta Garcia-Miralles; Janaky Coomaraswamy; Karina Häbig; Martin C Herzig; Natalja Funk; Frank Gillardon; Martina Maisel; Mathias Jucker; Thomas Gasser; Dagmar Galter; Saskia Biskup
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

10.  Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.

Authors:  Yunjong Lee; Senthilkumar S Karuppagounder; Joo-Ho Shin; Yun-Il Lee; Han Seok Ko; Debbie Swing; Haisong Jiang; Sung-Ung Kang; Byoung Dae Lee; Ho Chul Kang; Donghoon Kim; Lino Tessarollo; Valina L Dawson; Ted M Dawson
Journal:  Nat Neurosci       Date:  2013-08-25       Impact factor: 24.884

View more
  27 in total

Review 1.  Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Maria Nguyen; Yvette C Wong; Daniel Ysselstein; Alex Severino; Dimitri Krainc
Journal:  Trends Neurosci       Date:  2018-11-30       Impact factor: 13.837

Review 2.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

3.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.

Authors:  Nicolas Arbez; XiaoFei He; Yong Huang; Mark Ren; Yideng Liang; Frederick C Nucifora; Xiaofang Wang; Zhong Pei; Lino Tessarolo; Wanli W Smith; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

4.  Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.

Authors:  Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Caroline Menard; Meghan E Flanigan; Yue Zhong; Scott J Russo; Deanna L Benson; George W Huntley
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

5.  Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.

Authors:  Vered Shani; Hazem Safory; Raymonde Szargel; Ninghan Wang; Tsipora Cohen; Fatimah Abd Elghani; Haya Hamza; Mor Savyon; Inna Radzishevsky; Lihi Shaulov; Ruth Rott; Kah-Leong Lim; Christopher A Ross; Rina Bandopadhyay; Hui Zhang; Simone Engelender
Journal:  Hum Mol Genet       Date:  2019-12-01       Impact factor: 6.150

6.  On the Road from Phenotypic Plasticity to Stem Cell Therapy.

Authors:  Lorraine Iacovitti
Journal:  J Neurosci       Date:  2021-05-06       Impact factor: 6.167

Review 7.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

Review 8.  Dysfunction of Synaptic Vesicle Endocytosis in Parkinson's Disease.

Authors:  Li Zou; Ye Tian; Zhentao Zhang
Journal:  Front Integr Neurosci       Date:  2021-05-20

9.  Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration.

Authors:  Qinfang Liu; Judith Bautista-Gomez; Daniel A Higgins; Jianzhong Yu; Yulan Xiong
Journal:  Sci Signal       Date:  2021-07-27       Impact factor: 8.192

10.  The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Authors:  Noémie Cresto; Camille Gardier; Marie-Claude Gaillard; Francesco Gubinelli; Pauline Roost; Daniela Molina; Charlène Josephine; Noëlle Dufour; Gwenaëlle Auregan; Martine Guillermier; Suéva Bernier; Caroline Jan; Pauline Gipchtein; Philippe Hantraye; Marie-Christine Chartier-Harlin; Gilles Bonvento; Nadja Van Camp; Jean-Marc Taymans; Karine Cambon; Géraldine Liot; Alexis-Pierre Bemelmans; Emmanuel Brouillet
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.